EGFR and non-small cell lung carcinoma: The discovery of the EGFR mutation [23,24] and ALK rearrangement [24] and then the introduction of first-generation tyrosine kinase inhibitors (gefitinib—Figure 2A and erlotinib—Figure 2B) to the treatment of non-small cell lung carcinoma allowed, compared to platinum-based dual-drug chemotherapy, for longer progression-free survival (PFS), higher objective response rates (ORR), and better disease control rates (DCR) in comparison with two-drug platinum-derivative-based chemotherapy [23,24,25].